Jounce Story

<div class='circular--portrait' style='background:#169D0B;color: #E6E6FA;font-size:4em;'>JT</div>
JNCE -- USA Stock  

USD 8.16  0.07  0.85%

It looks like Precision BioSciences will continue to recover much faster as its share price surged up 5.12% today to Jounce Therapeutics's 23.7288%. As many rational traders are trying to avoid healthcare space, it makes sense to digest Jounce Therapeutics a little further and understand how it stands against Precision BioSciences and other similar entities. We are going to discuss some of the competitive aspects of both Jounce and Precision.
Published over a week ago
View all stories for Jounce Therapeutics | View All Stories
What is our outlook on Jounce (NASDAQ:JNCE) and Precision (NASDAQ:DTIL)?
By analyzing existing fundamental indicators between Jounce Therapeutics and Precision, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Precision with a short position in Jounce Therapeutics. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Jounce Therapeutics has an asset utilization ratio of 69.98 percent. This indicates that the company is making $0.7 for each dollar of assets. An increasing asset utilization means that Jounce Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Jounce or Dynavax is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Jounce Therapeutics's Liquidity

Jounce Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Jounce Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Jounce Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Jounce Therapeutics's total debt and its cash.

Correlation Between Jounce and Dynavax Technologies

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Jounce Therapeutics together with similar or unrelated positions with a negative correlation. For example, you can also add Dynavax Technologies to your portfolio. If Dynavax Technologies is not perfectly correlated to Jounce Therapeutics it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Jounce Therapeutics for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between JNCE and DVAX for more information.

Is Jounce Therapeutics valued correctly by the market?

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me take a closer look at Jounce Therapeutics revenue. Based on the latest financial disclosure, Jounce Therapeutics reported 119.44 M of revenue. This is 98.43% lower than that of the Healthcare sector and 83.92% lower than that of the Biotechnology industry. The revenue for all United States stocks is 98.73% higher than that of the entity. As for Precision BioSciences we see revenue of 19.46 M, which is 97.38% lower than that of the Biotechnology

Sector
742.9 M
JNCE119.44 Million13.54
Sector742.91 Million84.25
DTIL19.46 Million2.21

Our perspective of the latest Jounce Therapeutics surge

Jounce Therapeutics latest maximum drawdown ascents over 63.4. Jounce Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Jounce Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Jounce Therapeutics volatility.

The Bottom Line

Although other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Jounce Therapeutics may offer a potential longer-term growth to shareholders. The inconsistency in the assessment between current Jounce valuation and our trade advice on Jounce Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Jounce Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Jounce Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com